|
1
|
Chaugle F, Adams D, Rajagopal K. Use of venoarterial extracorporeal membrane oxygenation to bypass right-sided cardiac inflow obstruction. JTCVS Tech 2024; 26:73-75. [PMID: 39161545 PMCID: PMC11331812 DOI: 10.1016/j.xjtc.2024.05.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2024] [Revised: 05/12/2024] [Accepted: 05/15/2024] [Indexed: 08/21/2024] Open
Affiliation(s)
| | - Douglas Adams
- Division of Cardiovascular Anesthesia, Department of Anesthesiology, Thomas Jefferson University Hospital, Philadelphia, Pa
| | - Keshava Rajagopal
- Division of Cardiac Surgery, Department of Surgery, Thomas Jefferson University Hospital, Philadelphia, Pa
| |
Collapse
|
|
2
|
Sharma H, Nadir MA, Steeds RP, Doshi SN. Transcatheter valve-in-ring and para-ring vascular plug implantation for severe tricuspid regurgitation following annuloplasty ring failure: a case report. Eur Heart J Case Rep 2022; 6:ytac041. [PMID: 35233492 PMCID: PMC8874955 DOI: 10.1093/ehjcr/ytac041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2021] [Revised: 10/19/2021] [Accepted: 01/25/2022] [Indexed: 11/30/2022]
Abstract
Background Moderate or severe tricuspid regurgitation (TR) recurs in up to one-third of patients within 8 years of surgical annuloplasty repair. Reoperation often carries high risk with poor outcomes. Transcatheter valve-in-ring repair is an emerging alternative treatment. However, residual regurgitation is frequent and may necessitate further procedures. Case summary A 52-year-old female was diagnosed with severe rheumatic valvular heart disease. The patient underwent mechanical aortic and mitral valve replacement. Additionally, tricuspid repair was performed using a semi-rigid annuloplasty ring (28 mm Edwards Physio Tricuspid). Within 2 years, the patient developed recurrent, isolated severe symptomatic TR, with progressive right ventricular dilatation. The patient was considered prohibitive risk for redo surgery and unsuitable for cardiac transplantation. She underwent percutaneous valve-in-ring transcatheter heart valve (THV) implantation using a 29 mm Sapien S3 (Edwards Lifesciences, CA, USA) valve. Persistent severe residual para-ring TR warranted a further procedure to deploy vascular plugs, significantly reducing the TR to a mild jet with symptomatic improvement. Discussion Valve-in-ring THV implantation for failed surgical tricuspid annuloplasty repair is a rare procedure reserved for symptomatic patients at high or prohibitive risk for reoperation. Significant residual TR is a commonly encountered problem with incomplete annuloplasty rings following valve-in-ring procedures and may occur either intra-ring between the THV and the ring or para-ring. Implantation of vascular occlusion devices can be used to successfully treat residual TR at either location with good outcomes at 6-month follow-up. Further work is required to determine the longevity of this treatment.
Collapse
Affiliation(s)
- Harish Sharma
- Institute of Cardiovascular Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK
- Department of Cardiology, Queen Elizabeth Hospital Birmingham, Mindelsohn Way, Birmingham B15 2TH, UK
| | - M Adnan Nadir
- Institute of Cardiovascular Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK
- Department of Cardiology, Queen Elizabeth Hospital Birmingham, Mindelsohn Way, Birmingham B15 2TH, UK
| | - Richard P Steeds
- Institute of Cardiovascular Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK
- Department of Cardiology, Queen Elizabeth Hospital Birmingham, Mindelsohn Way, Birmingham B15 2TH, UK
| | - Sagar N Doshi
- Institute of Cardiovascular Sciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK
- Department of Cardiology, Queen Elizabeth Hospital Birmingham, Mindelsohn Way, Birmingham B15 2TH, UK
| |
Collapse
|
|
3
|
Mesnier J, Alperi A, Panagides V, Bédard E, Salaun E, Philippon F, Rodés-Cabau J. Transcatheter tricuspid valve interventions: Current devices and associated evidence. Prog Cardiovasc Dis 2021; 69:89-100. [PMID: 34801577 DOI: 10.1016/j.pcad.2021.11.007] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/14/2021] [Accepted: 11/14/2021] [Indexed: 11/15/2022]
Abstract
Tricuspid regurgitation (TR) is a common finding in patients with chronic cardiopathy, and often a marker of an advanced disease. Being silent or with symptoms intertwined with the primitive left heart disease, TR has often been neglected, leading to the late referral of patients with advanced right-heart failure. Hence, isolated tricuspid surgery has been associated with high morbidity and mortality rates, the worse of all valve interventions, and medical management has been limited to symptomatic treatment. In this context, percutaneous therapies for severe TR have gained traction, addressing the unmet therapeutic gap for a less invasive disease-modifying management. The aim of this review is to provide an updated overview on transcatheter tricuspid valve interventions, focusing on devices' characteristics, associated evidence, and future perspectives.
Collapse
Affiliation(s)
- Jules Mesnier
- Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada
| | - Alberto Alperi
- Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada
| | - Vassili Panagides
- Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada
| | - Elisabeth Bédard
- Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada
| | - Erwan Salaun
- Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada
| | - François Philippon
- Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada
| | - Josep Rodés-Cabau
- Quebec Heart and Lung Institute, Laval University, Quebec City, Quebec, Canada; Hospital Clínic Barcelona, Barcelona, Spain.
| |
Collapse
|
|
4
|
Simard TJ, Eleid MF. Transcatheter Tricuspid Valve Intervention: Current Perspective. US CARDIOLOGY REVIEW 2021; 15:e12. [PMID: 39720492 PMCID: PMC11664757 DOI: 10.15420/usc.2020.26] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2020] [Accepted: 03/14/2021] [Indexed: 12/18/2022] Open
Abstract
Tricuspid regurgitation (TR) adversely impacts both quality of life and long-term survival, which generates interest in therapeutic approaches to mitigate these effects. Historically, therapeutic options for TR were limited to surgical approaches, which are often complicated by significant morbidity and mortality in elderly patients with multiple comorbidities. This gap in therapeutic options led to the rapid evolution of transcatheter tricuspid valve intervention (TTVI), with a wide variety of approaches pursued and early results suggesting that TTVI improves clinical outcomes. Numerous strategies, including edge-to-edge repair, annular reduction, spacers, caval valve implantation, and transcatheter tricuspid valve replacement form the basis of TTVI today. In this review, the authors discuss the current state of each approach.
Collapse
Affiliation(s)
- Trevor J Simard
- Department of Cardiovascular Medicine, Mayo Clinic School of Medicine Rochester, MN
| | - Mackram F Eleid
- Department of Cardiovascular Medicine, Mayo Clinic School of Medicine Rochester, MN
| |
Collapse
|
|
5
|
Aoi S, Wiley J, Ho E, Goldberg Y, Chau M, Latib A. Transcatheter tricuspid valve implantation with the Cardiovalve system. Future Cardiol 2021; 17:963-969. [PMID: 33512242 DOI: 10.2217/fca-2020-0181] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Historically considered the 'forgotten valve', there has been increasing attention on the percutaneous transcatheter treatment of tricuspid regurgitation (TR). Prevalence of TR is high in the elderly population and prior studies have shown worse outcomes in patients with severe TR. Advances in transcatheter-based therapies have shed a new light in the treatment of TR and one such treatment option is tricuspid valve replacement with the Cardiovalve system. This device is approved as an early feasibility study in the US and also approved for clinical study in Germany, Italy and Switzerland. The Cardiovalve device is in the early stage of clinical studies and this article reviews the existing clinical data and future studies on percutaneous transcatheter treatment of severe TR.
Collapse
Affiliation(s)
- Shunsuke Aoi
- Department of Cardiology, Montefiore Medical Center, Bronx, NY 10467, USA
| | - Jose Wiley
- Department of Cardiology, Montefiore Medical Center, Bronx, NY 10467, USA
| | - Edwin Ho
- Department of Cardiology, Montefiore Medical Center, Bronx, NY 10467, USA
| | - Ythan Goldberg
- Department of Cardiology, Montefiore Medical Center, Bronx, NY 10467, USA
| | - Mei Chau
- Department of Cardiology, Montefiore Medical Center, Bronx, NY 10467, USA
| | - Azeem Latib
- Department of Cardiology, Montefiore Medical Center, Bronx, NY 10467, USA
| |
Collapse
|
|
6
|
Transcatheter Interventions for Tricuspid Valve Disease: What to Do and Who to Do It On. Can J Cardiol 2021; 37:953-967. [PMID: 33493660 DOI: 10.1016/j.cjca.2020.12.029] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2020] [Revised: 12/01/2020] [Accepted: 12/14/2020] [Indexed: 11/21/2022] Open
Abstract
Tricuspid valve disease, and particularly the management of severe tricuspid regurgitation (TR), has gained momentum in recent years. Although it is well known that this frequent condition is associated with poor clinical outcomes, these patients have been classically managed medically, leading to end-stage right ventricular heart failure. Moreover, late referral to surgery has contributed to a high rate of periprocedural complications and in-hospital surgical mortality. Thus, the development of a less invasive catheter-based therapy would be of high clinical relevance in this context. Several transcatheter tricuspid valve intervention (TTVI) devices have been developed in recent years. The particular characteristics of the tricuspid valve (large noncalcific annulus, presence of chief surrounding structures such as the conduction system or the right coronary artery) make multimodality imaging (eg, transesophageal echocardiography, computed tomography) key in the preprocedural assessment of TTVI. According to their mechanism of action and therapeutic target, TTVI includes transcatheter repair either with coaptation or annuloplasty systems, caval valve devices, and transcatheter tricuspid valve replacement. The initial TTVI experience showed that most procedures were well tolerated, with high procedural success and low in-hospital and early mortality. Also, most TTVI recipients improved their functional status and recent data suggest improved outcomes compared with medical management. However, the rate of significant residual TR after transcatheter tricuspid valve repair remains high and very scarce data exist on longer term (beyond 6-12 months) outcomes. The present review provides an overview regarding the framework of chronic TR and TTVI therapeutic options, and describes the updated current evidence in this challenging field.
Collapse
|
|
7
|
Cesna S, Eicken A. Percutaneous techniques for treatment of tricuspid valve dysfunction in congenital heart disease - an emerging therapy. Expert Rev Cardiovasc Ther 2020; 19:817-824. [PMID: 33336614 DOI: 10.1080/14779072.2021.1865154] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Abstract
Introduction: Tricuspid valve (TV) dysfunction treatment experiences exponential growth of the interest over the last years. New techniques for percutaneous tricuspid valve treatment are either on the market or in the early stages of development.Areas covered: Deficiency of uniform guideline-based recommendations leads to diverse TV dysfunction treatment options. The current review describes the development of surgical techniques for TV dysfunction in Ebstein's anomaly and transition to a variety of new technologies. Then, the focus is on the potential of percutaneous interventions to reduce the total number of open-heart surgeries in patients with congenital heart disease (CHD) after TV replacement with a bioprosthesis to improve TV function.Expert opinion: TV dysfunction is usually a complex combination of anatomical cardiac features in CHD. Compared to adults with secondary TV dysfunction, CHD patients usually are younger and have experienced several open-heart surgeries at a young age. Therefore, TV dysfunction can affect long-term life expectancy and quality of life significantly. So far, surgery was the gold standard for TV dysfunction treatment. The duration of TV plasty or bioprosthesis is limited, while the risk of re-do operations increases with every procedure. Percutaneous TV implantation may reduce the total number of open-heart surgeries over a patient's life.
Collapse
Affiliation(s)
- Sigitas Cesna
- Clinic of Cardiac and Vascular Diseases, Institute of Clinical Medicine, Vilnius University, Vilnius, Lithuania.,Centre of Cardiology and Angiology, Department of Cardiovascular Diseases, Vilnius University Hospital Santaros Clinics, Vilnius, Lithuania
| | - Andreas Eicken
- Department of Pediatric Cardiology and Congenital Heart Disease, German Heart Center, Munich, Technische Universität München, Munich, Germany
| |
Collapse
|
|
8
|
|
|
9
|
Morgan GJ, Sadeghi S, Salem MM, Wilson N, Kay J, Rothman A, Galindo A, Martin MH, Gray R, Ross M, Aboulhosn JA, Levi DS. SAPIEN valve for percutaneous transcatheter pulmonary valve replacement without “pre‐stenting”: A multi‐institutional experience. Catheter Cardiovasc Interv 2018; 93:324-329. [PMID: 30351525 DOI: 10.1002/ccd.27932] [Citation(s) in RCA: 47] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/11/2018] [Revised: 08/30/2018] [Accepted: 09/23/2018] [Indexed: 11/10/2022]
Affiliation(s)
- Gareth J. Morgan
- Division of Pediatric CardiologyChildren's Hospital of Colorado Aurora Colorado
- Division of CardiologyUniversity of Colorado Aurora Colorado
| | - Soraya Sadeghi
- Department of Pediatrics, Division of CardiologyUCLA Mattel Children's Hospital Los Angeles California
| | - Moris M. Salem
- Department of Pediatrics, Division of CardiologyKaiser Permanente Los Angeles California
| | - Neil Wilson
- Division of Pediatric CardiologyChildren's Hospital of Colorado Aurora Colorado
| | - Joseph Kay
- Division of CardiologyUniversity of Colorado Aurora Colorado
| | - Abraham Rothman
- Division of Pediatric CardiologyChildren's Heart Center of Nevada Las Vegas Nevada
| | - Alvaro Galindo
- Division of Pediatric CardiologyChildren's Heart Center of Nevada Las Vegas Nevada
| | - Mary Hunt Martin
- Division of Pediatric CardiologyPrimary Children's Hospital Salt Lake City Utah
| | - Robert Gray
- Division of Pediatric CardiologyPrimary Children's Hospital Salt Lake City Utah
| | - Michael Ross
- Division of Pediatric CardiologyChildren's Hospital of Colorado Aurora Colorado
| | - Jamil A. Aboulhosn
- Department of Medicine, Ahmanson Adult Congenital Heart Disease CenterDavid Geffen School of Medicine at UCLA Los Angeles California
| | - Daniel Steven Levi
- Department of Pediatrics, Division of CardiologyUCLA Mattel Children's Hospital Los Angeles California
- Department of Medicine, Ahmanson Adult Congenital Heart Disease CenterDavid Geffen School of Medicine at UCLA Los Angeles California
| |
Collapse
|
|
10
|
Sumski CA, Bartz P, Gudausky T. Percutaneous melody valve implantation in a native tricuspid valve following failed surgical repair. Catheter Cardiovasc Interv 2018; 92:1334-1337. [DOI: 10.1002/ccd.27872] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/18/2018] [Revised: 07/23/2018] [Accepted: 08/20/2018] [Indexed: 11/11/2022]
Affiliation(s)
- Christopher A. Sumski
- Department of Pediatrics, Children's Hospital of WisconsinHerma Heart Institute Milwaukee Wisconsin
| | - Peter Bartz
- Department of Cardiology, Children's Hospital of WisconsinHerma Heart Institute Milwaukee Wisconsin
| | - Todd Gudausky
- Department of Cardiology, Children's Hospital of WisconsinHerma Heart Institute Milwaukee Wisconsin
| |
Collapse
|
|
11
|
Revuelta JM, Pomar JL. La sustitución protésica de la válvula tricúspide: de Cenicienta a Princesa. CIRUGIA CARDIOVASCULAR 2018. [DOI: 10.1016/j.circv.2018.05.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022] Open
|
|
12
|
Asmarats L, Puri R, Latib A, Navia JL, Rodés-Cabau J. Transcatheter Tricuspid Valve Interventions. J Am Coll Cardiol 2018; 71:2935-2956. [DOI: 10.1016/j.jacc.2018.04.031] [Citation(s) in RCA: 183] [Impact Index Per Article: 26.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/03/2018] [Revised: 03/29/2018] [Accepted: 04/15/2018] [Indexed: 01/11/2023]
|
|
13
|
Abstract
Tricuspid regurgitation (TR) is a common entity, most commonly functional in nature due to right-sided dysfunction in the setting of concomitant cardiac disease or pulmonary hypertension. Patients living with TR often experience numerous limitations as a result of right-sided heart failure symptoms, including functional decline, frequent hospitalizations, liver failure, and kidney failure. Furthermore, patients with significant TR demonstrate worse survival, although a cause-and-effect relationship has not been proven. For patients with a degenerated surgical bioprosthesis or valve ring, placement of a transcatheter aortic valve prosthesis in a valve-in-valve or valve-in-ring fashion may provide symptomatic benefit. For patients with native valve regurgitation, novel devices for treatment are currently under development.
Collapse
Affiliation(s)
- Amar Krishnaswamy
- Section of Interventional Cardiology, Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA.
| | - Jose Navia
- Department of Cardiothoracic Surgery, Heart and Vascular Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA
| | - Samir R Kapadia
- Interventional Cardiology, Sones Cardiac Catheterization Laboratory, Heart and Vascular Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA
| |
Collapse
|
|
14
|
Rogkakou C, Braun P, Kullmer M, Schöls W. Transfemoral implantation of Edwards SAPIEN-XT ® transcatheter heart valve in a degenerated tricuspid bioprosthesis. J Cardiol Cases 2017; 16:131-133. [PMID: 30279816 PMCID: PMC6149287 DOI: 10.1016/j.jccase.2017.06.010] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2016] [Revised: 06/11/2017] [Accepted: 06/15/2017] [Indexed: 11/23/2022] Open
Abstract
We report on a percutaneous transcatheter valve-in-valve implantation (Edwards-SAPIEN-XT®) (Edwards Lifesciences Corp., One Edwards Way Irvine, CA 92614) in a 50-year-old i.v. drug user with a history of biological tricuspid valve replacement (Perimount 31 mm) (Edwards Lifesciences Corp., One Edwards Way Irvine, CA 92614) due to tricuspid valve endocarditis five years earlier. Re-operation was considered unfavorable due to general and specific risk factors. The case was discussed by the heart team. Obviously, some type of valve replacement was required. Given the high risk of tricuspid valve re-operation in general and the specific risk factors of the patient (New York Heart Association functional class III, reduced right ventricular function, continued drug abuse, active hepatitis C and human immunodeficiency virus infection, suspected non-compliance, unfavorable social background) the consensus was to attempt percutaneous transcatheter valve-in-valve implantation. Implantation of an Edwards-SAPIEN-XT® valve (Edwards Lifesciences Corp., One Edwards Way Irvine, CA 92614) in tricuspid position was successfully performed and the patient was transferred to the ward on day 2, completely free of symptoms. Pre-discharge echocadiographic control on day 6 again confirmed adequate position and regular function of the Edwards-SAPIEN-XT® valve (Edwards Lifesciences Corp., One Edwards Way Irvine, CA 92614) without any signs of regurgitation or stenosis. .
Collapse
Affiliation(s)
- Christina Rogkakou
- Evangelisches Klinikum Niederrhein — Duisburg Heart Center, Duisburg, Germany
| | | | | | | |
Collapse
|
|
15
|
Abstract
Only 75% of severe tricuspid regurgitation is classified as functional, or related primarily to pulmonary hypertension, right ventricular dysfunction, or a combination of both. Non-functional tricuspid regurgitation occurs when there is damage to the tricuspid leaflets, chordae, papillary muscles, or annulus, independent of right ventricular dysfunction or pulmonary hypertension. The entities that cause non-functional tricuspid regurgitation include rheumatic and myxomatous disease, acquired and genetic connective tissue disorders, endocarditis, sarcoid, pacing, RV biopsy, blunt trauma, radiation, carcinoid, ergot alkaloids, dopamine agonists, fenfluramine, cardiac tumors, atrial fibrillation, and congenital malformations. Over time, severe tricuspid regurgitation that is initially non-functional, can blend into functional tricuspid regurgitation, related to progressive right ventricular dysfunction. Symptoms and signs, including a falling right ventricular ejection fraction, cardiac cirrhosis, ascites, esophageal varices, and anasarca, may occur insidiously and late, but are associated with substantial morbidity and mortality. Attempted valve repair or replacement at late stages carries a high mortality. Crucial to following patients with severe non-functional tricuspid regurgitation is attention to echo quantification of the tricuspid regurgitation and right ventricular function, patient symptoms, and the physical examination.
Collapse
Affiliation(s)
- Dale S Adler
- Division of Cardiovascular Diseases, Brigham & Women's Hospital, Harvard Medical School, Boston, MA, USA
| |
Collapse
|
|
16
|
|
|
17
|
Transcatheter Valve-in-Ring Implantation for the Treatment of Residual or Recurrent Tricuspid Valve Dysfunction After Prior Surgical Repair. JACC Cardiovasc Interv 2017; 10:53-63. [DOI: 10.1016/j.jcin.2016.10.036] [Citation(s) in RCA: 68] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/05/2016] [Revised: 10/11/2016] [Accepted: 10/20/2016] [Indexed: 11/22/2022]
|
|
18
|
Levi DS, Sinha S, Salem MM, Aboulhosn JA. Transcatheter native pulmonary valve and tricuspid valve replacement with the sapien XT: Initial experience and development of a new delivery platform. Catheter Cardiovasc Interv 2016; 88:434-43. [PMID: 27142960 DOI: 10.1002/ccd.26398] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/01/2015] [Revised: 12/15/2015] [Accepted: 12/21/2015] [Indexed: 11/11/2022]
Affiliation(s)
- Daniel S. Levi
- Department of Pediatrics, Division of Cardiology; UCLA Mattel Children's Hospital; Los Angeles California
| | - Sanjay Sinha
- Department of Pediatrics, Division of Cardiology; UCLA Mattel Children's Hospital; Los Angeles California
| | - Morris M. Salem
- Department of Pediatrics, Division of Cardiology; Kaiser Permanente; Los Angeles California
| | - Jamil A. Aboulhosn
- Department of Medicine; Ahmanson Adult Congenital Heart Disease Center, David Geffen School of Medicine at UCLA; Los Angeles California
| |
Collapse
|
|
19
|
Tricuspid valve and percutaneous approach: No longer the forgotten valve! Arch Cardiovasc Dis 2016; 109:55-66. [DOI: 10.1016/j.acvd.2015.08.002] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/28/2015] [Accepted: 08/03/2015] [Indexed: 10/22/2022]
|
|
20
|
Condado J, Leonardi R, Babaliaros V. Percutaneous tricuspid valve-In-ring replacement for the treatment of recurrent severe tricuspid regurgitation. Catheter Cardiovasc Interv 2015; 86:1294-8. [DOI: 10.1002/ccd.25980] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/25/2014] [Revised: 03/02/2015] [Accepted: 04/06/2015] [Indexed: 11/08/2022]
Affiliation(s)
- Jose Condado
- Structural Heart and Valve Center; Division of Cardiology; Emory University School of Medicine; Atlanta Georgia
| | - Robert Leonardi
- Structural Heart and Valve Center; Division of Cardiology; Emory University School of Medicine; Atlanta Georgia
| | - Vasilis Babaliaros
- Structural Heart and Valve Center; Division of Cardiology; Emory University School of Medicine; Atlanta Georgia
| |
Collapse
|
|
21
|
Wagner R, Daehnert I, Lurz P. Percutaneous pulmonary and tricuspid valve implantations: An update. World J Cardiol 2015; 7:167-177. [PMID: 25914786 PMCID: PMC4404372 DOI: 10.4330/wjc.v7.i4.167] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/28/2014] [Revised: 01/08/2015] [Accepted: 02/12/2015] [Indexed: 02/06/2023] Open
Abstract
The field of percutaneous valvular interventions is one of the most exciting and rapidly developing within interventional cardiology. Percutaneous procedures focusing on aortic and mitral valve replacement or interventional treatment as well as techniques of percutaneous pulmonary valve implantation have already reached worldwide clinical acceptance and routine interventional procedure status. Although techniques of percutaneous pulmonary valve implantation have been described just a decade ago, two stent-mounted complementary devices were successfully introduced and more than 3000 of these procedures have been performed worldwide. In contrast, percutaneous treatment of tricuspid valve dysfunction is still evolving on a much earlier level and has so far not reached routine interventional procedure status. Taking into account that an “interdisciplinary challenging”, heterogeneous population of patients previously treated by corrective, semi-corrective or palliative surgical procedures is growing inexorably, there is a rapidly increasing need of treatment options besides redo-surgery. Therefore, the review intends to reflect on clinical expansion of percutaneous pulmonary and tricuspid valve procedures, to update on current devices, to discuss indications and patient selection criteria, to report on clinical results and finally to consider future directions.
Collapse
|
|
22
|
Schofer J, Bijuklic K, Tiburtius C, Hansen L, Groothuis A, Hahn RT. First-in-Human Transcatheter Tricuspid Valve Repair in a Patient With Severely Regurgitant Tricuspid Valve. J Am Coll Cardiol 2015; 65:1190-1195. [DOI: 10.1016/j.jacc.2015.01.025] [Citation(s) in RCA: 156] [Impact Index Per Article: 15.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/25/2014] [Revised: 12/29/2014] [Accepted: 01/14/2015] [Indexed: 11/17/2022]
|
|
23
|
Mortazavi A, Reul RM, Cannizzaro L, Dougherty KG. Transvenous transcatheter valve-in-valve implantation after bioprosthetic tricuspid valve failure. Tex Heart Inst J 2014; 41:507-10. [PMID: 25425983 DOI: 10.14503/thij-14-4302] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
We describe the case of a 38-year-old man with a history of metastatic testicular cancer who had undergone multiple thoracic surgical procedures, including tricuspid valve replacement with a bioprosthetic valve as a result of tricuspid involvement of his malignancy. He presented at our outpatient cardiology clinic with worsening fatigue, shortness of breath, and peripheral edema, investigation of which revealed severe tricuspid bioprosthesis stenosis with central regurgitation. Because of the patient's medical history, he was considered to be a high-risk surgical candidate. Therefore, transcatheter tricuspid valve-in-valve implantation of a 26-mm Edwards Sapien(®) valve was attempted through a transjugular approach. The procedure restored tricuspid valvar competence and substantially improved the patient's symptoms. We discuss the technical aspects of this case and briefly review the usefulness of the valve-in-valve technique in the tricuspid position.
Collapse
|
|
24
|
Kuetting M, Pott D, Sedaghat A, Ng YA, Egron S, Rosefort C, Werner N, Sachweh J, Steinseifer U. Right heart transcatheter valve therapies – a review of prostheses for the pulmonary and tricuspid positions. Expert Rev Med Devices 2014; 12:163-74. [DOI: 10.1586/17434440.2015.985654] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
|
25
|
Transcatheter tricuspid valve implantation: A multicentre French study. Arch Cardiovasc Dis 2014; 107:583-91. [DOI: 10.1016/j.acvd.2014.07.051] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/30/2014] [Revised: 07/17/2014] [Accepted: 07/23/2014] [Indexed: 01/27/2023]
|
|
26
|
Ramakrishna H, Augoustides JGT, Gutsche JT, Stein E, Weiss SJ, Vernick WJ. Incidental tricuspid regurgitation in adult cardiac surgery: focus on current evidence and management options for the perioperative echocardiographer. J Cardiothorac Vasc Anesth 2014; 28:1414-20. [PMID: 25319991 DOI: 10.1053/j.jvca.2014.04.008] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/17/2014] [Indexed: 11/11/2022]
Affiliation(s)
| | - John G T Augoustides
- Cardiovascular and Thoracic Section, Department of Anesthesiology and Critical Care, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.
| | - Jacob T Gutsche
- Cardiovascular and Thoracic Section, Department of Anesthesiology and Critical Care, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
| | - Erica Stein
- Department of Anesthesiology, Ohio State University, Columbus, OH
| | - Stuart J Weiss
- Cardiovascular and Thoracic Section, Department of Anesthesiology and Critical Care, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
| | - William J Vernick
- Cardiovascular and Thoracic Section, Department of Anesthesiology and Critical Care, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
| |
Collapse
|